Decrease in susceptibility toward induction of apoptosis and alteration G1 in checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine)

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4406-4412

  Sugiyama, Kazuyo ^a   Akiyama, Tadakazu ^a   Shimizu, Makiko ^a   Tamaoki, Tatsuya ^a   Courage, Carol ^b   Gescher, Andreas ^b   Akinaga, Shiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; DOXORUBICIN; FLAVOPIRIDOL; MIDOSTAURIN; MITOMYCIN C; NAVELBINE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; STAUROSPORINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG RESISTANCE, NEOPLASM; G1 PHASE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0033198465     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Takahashi, I., Kobayashi, E., Asano, K., Yoshida, M., and Nakano, H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot., 40: 1782-1784, 1987.
2. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res., 51: 4888-4892, 1991.
3. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
4. Pollack, I. F., Kawecki, S., and Lazo, J. S. Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J. Neurosurg., 84: 1024-1032, 1996.
5. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
6. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ., 6: 927-936, 1995.
7. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Jr., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., Van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E., and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science (Washington DC), 275: 343-349, 1997.
8. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Synergistic antitumor effect of UCN-01, a protein kinase C inhibitor, combined with various anti-cancer agents. Proc. Am. Assoc. Cancer Res., 33: 514, 1992.
9. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother. Pharmacol., 33: 273-280, 1994.
10. 2 abrogation which might be dependent on mutated p53 protein function. Proc. Am. Assoc. Cancer Res., 39: 70, 1998.
11. 2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
12. Hsueh, C. T., Kelsen, D., and Schwartz, G. K. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res., 4: 2201-2206, 1998.
13. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
14. 1 regulation in A431 cells synchronized at M phase by nocodazole. Anticancer Drugs, 10: 67-78, 1999.
15. Kawakami, K., Futami, H., Takahara, J., and Yamaguchi, K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem. Biophys. Res. Commun., 219: 778-783, 1996.
16. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/ Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57: 1495-1501, 1997.
17. Shao, R. G., Shimizu, T., and Pommier, Y. 7-hydroxystaurospoine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp. Cell Res., 234: 388-397, 1997.
18. Shao, R. G., Cao, C. X., and Pommier, Y. Activation of PKCα downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL-60 cells. J. Biol. Chem., 272: 31321-31325, 1997.
19. Courage, C., Bradder, S. M., Jones, T., Schultze-Mosgau, M. H., and Gescher, A. Characterization of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine. Int. J. Cancer, 73: 763-768, 1997.
20. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
21. Gorczyca, W., Bruno, S., Darzynkiewicz, R. J., Gong, J., and Darzynkiewicz, Z. DNA strand breaks occurring during apoptosis: their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int. J. Oncol., 1: 639-648, 1992.
22. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villaba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998.
23. Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marmé, D., and Rapp, U. R. Protein kinase Cα activates RAF-1 by direct phosphorylation. Nature (Lond.), 364: 249-252, 1993.
24. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
25. Ling, Y-H., Tornos, C., and Perez-Soler, R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J. Biol. Chem., 273: 18984-18991, 1998.
26. Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D., Figg, W. D., Arbuck, S. G., Senderowicz, A. M., Sausville, E. A., Akinaga, S., Kuwabara, T., and Kobayashi, S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein. Cancer Res., 58: 3248-3253, 1998.
27. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
28. Nakayama, K., and Nakayama, K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. BioEssays, 20: 1020-1029, 1998.
29. Poruchynsky, M. S., Wang, E. E., Rudin, C. M., Blagosklonny, M. V., and Fojo, T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res., 58: 3331-3338, 1998.
30. Huang, D. C. S., O'Reilly, L. A., Strasser, A., and Cory, S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J., 16: 4628-4638, 1997.
31. Elliott, M. J., Stribinskiene, L., and Lock, R. B. Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. Cancer Chemother. Pharmacol., 41: 457-463, 1998.
32. Kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. Mol. Cell, 1: 553-563, 1998.
33. Cip1/Waf1 by caspases is an early event during DNA damage-induced apoptosis. J. Biol. Chem., 273: 19207-19212, 1998.
34. WAF1/CIP1 in the earlier stage of apoptosis in SK-HEP-1 human hepatoma cells. Eur. J. Biochem., 257: 242-248, 1998.
35. Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
36. KIp1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int. J. Cancer, 77: 496-802, 1998.
37. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science (Washington DC), 274: 1664-1672, 1996.